Treatment with natalizumab in relapsing-remitting multiple sclerosis patients induces changes in inflammatory mechanism
Journal of Clinical Immunology, ISSN: 0271-9142, Vol: 31, Issue: 4, Page: 623-631
2011
- 45Citations
- 50Captures
Metric Options: Counts1 Year3 YearSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations45
- Citation Indexes45
- 45
- CrossRef27
- Captures50
- Readers50
- 50
Article Description
Natalizumab is a widely accepted drug for the relapsing-remitting subtype of multiple sclerosis (RRMS). The present longitudinal exploratory study in RRMS patients analyzes the effects of natalizumab treatment on the levels of pro-inflammatory and anti-inflammatory cytokine protein levels and also the frequency and suppressor function of regulatory T cells. Flow cytometry was used to determine cytokines and regulatory T cell frequency while regulatory T cell suppressor function was assayed in vitro at different time-points after starting with natalizumab. Results showed serum levels of proinflammatory interferon gamma and interleukin (IL)- 12p70, as well as anti-inflammatory IL-4 and IL-10, were elevated just a few hours or days after first IV infusion of natalizumab. Interestingly, other cytokines like IL-5 or IL- 13 were also elevated while pro-inflammatory IL-17, IL-2, and IL-1ß increased only after a long-term treatment, suggesting different immune mechanisms. In contrast, we did not observe any effect of natalizumab treatment on regulatory T cell frequency or activity. In conclusion, these results suggest natalizumab has other immunological effects beyond VLA-4 interaction and inhibition of CNS extravasation, the relevance of which is as yet unknown and warrants further investigation. © Springer Science+Business Media, LLC 2011.
Bibliographic Details
http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=80555150830&origin=inward; http://dx.doi.org/10.1007/s10875-011-9522-x; http://www.ncbi.nlm.nih.gov/pubmed/21491095; http://link.springer.com/10.1007/s10875-011-9522-x; https://dx.doi.org/10.1007/s10875-011-9522-x; https://link.springer.com/article/10.1007/s10875-011-9522-x; http://www.springerlink.com/index/10.1007/s10875-011-9522-x; http://www.springerlink.com/index/pdf/10.1007/s10875-011-9522-x
Springer Nature
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know